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Abstract
Background: We evaluated the hierarchical risk groups for the estimated survival of WHO grade
III glioma patients using recursive partitioning analysis (RPA). To our knowledge, this is the first
study to address the results of RPA specifically for WHO grade III gliomas.
Methods:  A total of 133 patients with anaplastic astrocytoma (AA, n = 56), anaplastic
oligodendroglioma (AO, n = 67), or anaplastic oligoastrocytoma (AOA, n = 10) were included in
the study. These patients were treated with either radiotherapy alone or radiotherapy followed by
PCV chemotherapy after surgery. Five prognostic factors, including histological subsets, age,
performance status, extent of resection, and treatment modality were incorporated into the RPA.
The final nodes of RPA were grouped according to their survival times, and the Kaplan-Meier
graphs are presented as the final set of prognostic groups.
Results: Four risk groups were defined based on the clinical prognostic factors excluding age, and
split variables were all incorporated into the RPA. Survival analysis showed significant differences
in mean survival between the different groups: 163.4 months (95% CI: 144.9-182.0), 109.5 months
(86.7-132.4), 66.6 months (50.8-82.4), and 27.7 months (16.3-39.0), respectively, from the lowest
to the highest risk group (p = 0.00).
Conclusion: The present study shows that RPA grouping with clinical prognostic factors can
successfully predict the survival of patients with WHO grade III glioma.
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Background
Anaplastic astrocytoma (AA), anaplastic oligodendrogli-
oma (AO), and anaplastic oligoastrocytoma (AOA) are
defined as the major histological categories of WHO grade
III gliomas, even though their classification based on the
known molecular biology information remains contro-
versial [1-4]. The relative survival rates at 5 years for AA
and AO are 29.4% and 45.2%, respectively[5]. Although
the increase is modest, standardized radiotherapy or
chemotherapy has extended the survival period for
patients with high-grade gliomas, suggesting the possible
influence of prognostic factors such as age, performance
status, symptom duration, tumor resection, histological
type, and 1p/19q co-deletion [6-8]. However, most rand-
omized trials pooled both grades III or IV astrocytic
tumors and grade III oligodendroglial tumors as malig-
nant glioma[7,8]. The only exceptions are the studies on
PCV chemotherapy for AO[9,10]. A separate study of
WHO grade III glioma is needed because of the observed
difference in the outcome for grade IV glioblastoma using
the same treatment protocols[11,12]. Even in those well-
designed studies employing consistent treatment proto-
cols, diverse biological behaviors and clinical outcomes
clearly exist for patients with AA, AO, and AOA. Therefore,
the prediction of survival outcomes for WHO grade III gli-
oma patients based on known clinical prognostic factors
attains importance with regard to the treatment plan.
Recursive partitioning analysis (RPA) classification, which
was initially described by the Radiation Therapy Oncol-
ogy Group (RTOG), is a useful tool that can divide
patients into homogenous groups based on the length of
survival[13]. RPA has an advantage over the proportional
hazards model in identifying prognostic factors because it
makes fewer modeling assumptions and has an estab-
lished procedure that adapts to missing data through the
use of surrogate measures[14]. Moreover, development of
high-speed computer systems has made this tedious work
easy for researchers[14]. The RTOG presented results from
an RPA for all patients with malignant glioma (both
WHO grade III and IV) throughout the duration of their
clinical trials[13]. Results obtained for re-analysis of clin-
ical trials using RPA, which focused only on glioblastoma
patients, were also reported[14].
We evaluated the prognostic factors in the distinct group
of newly diagnosed WHO grade III patients who were
treated with radiotherapy or radiotherapy plus chemo-
therapy (PCV regimen) after surgery, in an attempt to pre-
dict survival outcomes by RPA. To our knowledge, this is
the first study to address the RPA results focused specifi-
cally on WHO grade III gliomas.
Methods
A total of 133 newly diagnosed AA, AO, and AOA patients
were included in this single-center retrospective study.
These patients were treated at the Seoul National Univer-
sity Hospital between January 1990 and December 2004,
according to the baseline protocol, either with radiother-
apy alone or with radiotherapy plus PCV chemotherapy.
Histological diagnosis was re-evaluated according to the
WHO 2000 classification. Patient data were collected
according to the guidance specifications approved by the
institutional review board and included information con-
tained within the hospital charts and radiological studies.
Clinical data such as age, performance status, extent of
resection, and primary treatment modality after surgery
were collected. Data that were unavailable in the medical
records due to follow-up loss were obtained via a tele-
phone interview with the patient or, if the patient was
deceased, with his or her relatives with their permission.
The survival time was measured from the date of surgery
to the date of the patient's death. Patients who were alive
were classified as censored observations at the time of the
last follow-up. Variables selected for prognosis analysis
were those that were determined as significant based on
previous reports[7-9,11,15]. Age was classified as 50 and
above or under 50. Performance status was scored accord-
ing to the Eastern Cooperative Oncology Group (ECOG)
scales[16]. The extent of resection was categorized as a
complete resection or incomplete resection (including
biopsy only) based on the immediate post-operative
imaging findings. Residual enhancing lesion on T1-
enhanced images or measurable high signal intensity
lesion on T2 images without enhancement of magnetic
resonance images were considered residual lesion. Histo-
logical diagnosis and base-line treatment protocols were
also included in the analysis.
The Kaplan-Meyer method was used to estimate the over-
all survival distributions. The log-rank test (level of signif-
icance α = 0.05) was used to test the differences in the
overall survival distributions with respect to prognostic
variables. A Cox proportional hazards model (level of sig-
nificance α = 0.05) was used to adjust for covariates. These
analyses were performed using SPSS® ver 12.0. During
RPA, free software (R version 2.6.2; rpart package version
3.1.39-1, http://www.r-project.org/) was used for the
recursive decision tree creation with the split criteria of p
< 0.01 in the log-rank test. The final nodes were grouped
according to their survival times, and the Kaplan-Meier
graphs are presented as the final set of prognostic groups.
Results
The baseline clinical data of the study population are
summarized in Table 1. Among 133 patients, 56 patients
had a histological diagnosis of AA, 67 had AO, and 10 had
AOA. The mean follow-up period of whole population
was 88.8 months. The age distributions at the time of
diagnosis, performance status, and baseline treatment
were comparable among the groups defined by the histo-BMC Cancer 2009, 9:450 http://www.biomedcentral.com/1471-2407/9/450
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logical diagnosis. A predilection for incomplete resection
of tumors was apparent in the AA group due to their dif-
fuse infiltrating nature of growth. Radiotherapy alone was
part of the baseline treatment protocol before the mid-
1990s (n = 67), and 6 to 12 cycles of PCV (procarbazine,
lomustine, and vincristine) chemotherapy were added
after radiotherapy beginning in the late-1990s (n = 66). In
all patients, radiotherapy was initiated within 6 weeks
after the surgery with a total mean dose of 59.4 Gy, 1.8 Gy
per fraction with five fractions per week. The target vol-
ume included the residual tumor volume or surgical cav-
ity and surrounding edema with a margin of 3 cm. Seven
patients could not complete the planned dose of radio-
therapy due to intolerance. PCV chemotherapy started
within 4 weeks after the end of RT. Each cycle consisted of
lomustine 110 mg/m2 orally on day 1, procarbazine 60
mg/m2 orally on days 8 to 21, and vincristine 1.4 mg/m2
intravenous on days 8 and 29. Cycles were to be repeated
every 6 weeks. The mean number of cycles completed per
patient was 5.8. Due to the intolerance, 42% of patients
were treated with less than 6 cycles of PCV.
The median overall survival of the entire population was
59.0 months (95% confidence interval = 38.0 through
80.0). Estimated survival rates at 1-, 2-, 5-, and 10-years
were 84.9%, 72.8%, 49.1%, and 35.5%, respectively. Sur-
vival was significantly better in radiotherapy plus PCV
group (mean 118.0 months; 95% confidence interval =
100.7 through 135.4, median not reached) than radio-
therapy only group (mean 57.7 months; 95% confidence
interval = 41.7 through 73.8, median 29.0 months; 95%
confidence interval = 19.2 through 38.9) (p = 0.00).
All possible prognostic variables determined as significant
affected the overall survival in the univariate analysis. The
results of the univariate analysis on median survival are as
follows; age (65 months in < 50 years vs 19 months in ≥
50 years), performance status (53 months in ECOG grade
1 vs 13 months in ECOG grade 2 (survivals showed strat-
ification with ECOG grade and showed significant split
between grade 1 and 2)), histology (29 months in AA vs
37 months in AOA vs 79 months in AO), and extent of
resection (median survival not reached in complete resec-
tion vs 19 months in incomplete resection). The results of
the Cox proportional-hazard analysis using these prog-
nostic variables showed that the prolonged overall sur-
vival was independently affected by young age, good
performance status, histological diagnosis of AO, com-
plete resection, or addition of adjuvant PCV chemother-
apy after radiotherapy (Table 2).
Using the above mentioned significant prognostic varia-
bles, a recursive decision tree comprising 132 patients was
created after exclusion of one patient during the analysis
due to short survival time (less than 1 month). A total of
8 terminal nodes were produced in 6 splits (Figure 1).
Among the variables included in the RPA, age was omitted
from the split criteria according to the order of priority.
Based on the median survival time of the terminal nodes,
we were able to categorize them into four groups (Table
3). Survival analysis using the Kaplan-Meyer and log-rank
test confirmed the significant differences among groups
(p = 0.00, Figure 2). Independent of the histological diag-
nosis, patients treated with radiotherapy plus PCV chem-
otherapy after complete resection, or after incomplete
resection but with the best performance status (ECOG
grade 0), can expect the longest survival (Group A). Using
the present results, survival probabilities can be estimated
based on post-surgical clinical settings.
Table 1: Baseline characteristics of the study population (number of patients).
AA AO AOA Total
(n = 56) (n = 67) (n = 10) (n = 133)
Age at diagnosis
≥50 years 16 (28.6%) 17 (25.4%) 3 (30.0%) 36 (27.1%)
< 50 years 40 (71.4%) 50 (74.6%) 7 (70.0%) 97 (72.9%)
Performance status
ECOG grade 0 5 (8.9%) 10 (14.9%) 2 (20.0%) 17 (12.8%)
ECOG grade 1 38 (67.8%) 44 (65.7%) 5 (50.0%) 87 (65.4%)
ECOG grade 2 9 (16.1%) 7 (10.4%) 0 16 (12.0%)
ECOG grade 3 2 (3.6%) 5 (7.5%) 3 (30.0%) 10 (7.5%)
ECOG grade 4 2 (3.6%) 1 (1.5%) 0 3 (2.3%)
Extent of resection
complete 6 (10.7%) 27 (40.3%) 3 (30.0%) 36 (27.1%)
incomplete 50 (89.3%) 40 (59.7%) 7 (70.0%) 97 (72.9%)
Baseline treatment
radiotherapy 31 (55.3%) 31 (46.3%) 5 (50.0%) 67 (50.3%)
radiotherapy plus PCV** 25 (44.7%) 36 (53.7%) 5 (50.0%) 66 (49.7%)
ECOG: Eastern Cooperative Oncology Group
PCV: procarbazine, lomustine, and vincristineBMC Cancer 2009, 9:450 http://www.biomedcentral.com/1471-2407/9/450
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Discussion
Although AA, AO, and AOA are grouped as the same his-
tological grade by the WHO classification system, among
them exist diverse biological behaviors linked to clinical
outcome, even within the same histological diagnosis.
However, straightforward comparative analyses of the
prognostic factors among the WHO grade III gliomas have
been reported infrequently. In the present study, hierar-
chical stratification of prognostic variables, such as per-
formance status, histological diagnosis, extent of
resection, and adjuvant chemotherapy after radiotherapy
among the WHO grade III gliomas could be deduced suc-
cessfully using the RPA method. Based on the results of
the present study, several conclusions could be drawn: (1)
good complete resection is the most important prognostic
factor for performance status, (2) the oligodendroglial
component of the tumor favors better prognosis, and (3)
PCV chemotherapy may be beneficial for certain groups of
patients. These findings are not novel; however, using the
risk group splits according to the given condition of the
Table 2: Multivariate Cox proportional-hazards results for the prognostic value of variables related to the survival of WHO grade III 
glioma patients (n = 131).
Hazard ratio p value 95% confidence interval
Age ≥ 50 years 2.212 0.002 1.341-3.648
ECOG grade ≥ 2 2.179 0.003 1.305-3.638
AO 0.406 0.000 0.250-0.660
Complete resection 0.433 0.014 0.222-0.845
Radiotherapy plus PCV† 0.335 0.000 0.201-0.558
ECOG: Eastern Cooperative Oncology Group
AO: anaplastic oligodendroglioma
PCV: procarbazine, lomustine, and vincristine
Decision tree constructed by recursive partitioning analysis Figure 1
Decision tree constructed by recursive partitioning analysis. Terminal nodes () are categorized into 4 groups based 
on their median survival times.BMC Cancer 2009, 9:450 http://www.biomedcentral.com/1471-2407/9/450
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patients, we can estimate survival based on the chosen
treatment modalities.
According to various studies, age is an invariably impor-
tant prognostic factor of performance status for WHO
grade III glioma[8,13,17,18]. We also observed significant
prognostic values for performance status in the present
analysis. However, it is important to note that age was
excluded as a factor during the RPA, although it was a sig-
nificant variable in the univariate analysis.
Analysis of the extent of resection for WHO grade III glio-
mas was based on the available data collected in an
uncontrolled study setting. The present analysis has pit-
falls, such as that superficial, small, well-demarcated
tumors tend to undergo complete resection, whereas
deep-seated, extensive, diffuse tumors are more likely to
undergo biopsy only or incomplete resection[7,8]. Evi-
dence for the prognostic impact of the extent of resection
on AA remains sparse[19]; however, randomized studies
investigating a combination of multiple treatment modal-
Survival plot of the risk groups defined in Table 3 Figure 2
Survival plot of the risk groups defined in Table 3. Kaplan-Meyer analysis and the log-rank test revealed significant differ-
ences among the groups (p = 0.00).
Table 3: Risk group splits according to the results of recursive partitioning analysis.
Risk group Number of patients Number of events
Group A RT-PCV, CR 25 3
RT-PCV, ECOG 0, ICR
Group B RT-PCV, ECOG>0, ICR, AO/AOA 38 17
RT, ECOG<2, CR
Group C RT-PCV, ECOG>0, ICR, AA 34 25
RT, ECOG<2, ICR, AO/AOA
Group D RT, ECOG<2, ICR, AA 35 31
RT, ECOG≥ 2
RT: radiotherapy
PCV: procarbazine, lomustine, and vincristine
CR: complete resection
ICR: incomplete resection
ECOG: Eastern Cooperative Oncology Group
AO: anaplastic oligodendroglioma
AOA: anaplastic oligoastrocytoma
AA: anaplastic astrocytomaBMC Cancer 2009, 9:450 http://www.biomedcentral.com/1471-2407/9/450
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ities support the beneficial impact of complete resection
for AO and AOA[9,10].
Better prognosis of oligodendroglial tumors over astro-
cytic tumors is also supported by previous studies[20].
This evidence was further investigated, and the underlying
genetic signature, such as the 1p/19q co-deletion in oli-
godendroglial tumors, was found to be responsible for the
favorable prognosis[9]. Moreover, the diffuse nature of AA
that precludes complete resection might have affected the
outcome. It is a limitation of the present study that we
could not include any molecular markers into RPA due to
unavailability of appropriate tissue samples to carry on
the analysis.
Radiotherapy and PCV chemotherapy, along with other
alkylating agents such as nitrosoureas and temozolomide,
are still considered to be the major options for the man-
agement of AA, AO, and AOA patients. Nonetheless, the
role of radiotherapy in the treatment of AO/AOA and that
of PCV chemotherapy for AA still requires further investi-
gation [21-24]. Although the results of the present study
show a beneficial effect of PCV chemotherapy on the out-
come of the multivariate analysis, the possibility of a
selection bias remains, since patients with poor perform-
ance status were excluded from further chemotherapy.
Another noteworthy finding of the present study is the
evidence for the diversity of the prognosis of AA, AO, and
AOA patients, despite the best available treatment. The
estimated survival ranged from good (group A) to bad
(group D, such as glioblastoma) status. The results imply
that AA, AO, and AOA patients with the best performance
status, or with completely extirpated tumors, can be main-
tain prolonged survival without any recurrence with radi-
otherapy followed by PCV chemotherapy.
There are many clinical studies employing RPA to define
risk groups[14,25-28]. RPA is a robust tool for the stratifi-
cation of prognostic factors and for the identification of a
homogenous group of patients for a given disease and
treatment strategy. However, there are limitations to RPA
application. For example, it is a post-hoc test, and no pre-
dictions can be made using the final splits, since prognos-
tic factors are selected by chance[14]. If multiple variables
that are highly correlated exist, the selection of factors may
vary[14]. Despite these limitations, the RPA method
allows for a clear distinction between the WHO grade III
glioma patients risk groups. The advantage of this study is
that only those patients with WHO grade III glioma who
received the best available treatment were included in the
analysis. It is more likely that the novel anticancer agent
such as temozolomide will take over the mainstream of
WHO grade III glioma management sooner or later. How-
ever, we believe that the systemized analysis for classic
management has its own significance because it can be
solid reference for the upcoming new therapeutic strate-
gies.
Conclusion
The present study shows that RPA grouping can success-
fully predict the survival of patients with WHO grade III
glioma. Performance status, extent of resection, histologi-
cal diagnosis, and treatment modality are the major deter-
minants of patients' survival. These results may provide a
tool for the collection of baseline data for further investi-
gation of treatment modalities in the different risk groups
of patients.
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